Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

No Relief In Sight For Future Of OTC Asthma Products

This article was originally published in The Tan Sheet

Executive Summary

The slated removal of OTC epinephrine inhalers from the market in 28 months raises questions about whether affordable alternatives will be available and whether FDA would approve another nonprescription asthma drug

You may also be interested in...



Primatene Mist Chances To Remain On Market Dwindle With Senate Vote

Primatene Mist Chances To Remain On Market Dwindle With Senate Vote

Armstrong Says FDA "Assured" OTC Access Of Reformulated Primatene Mist

Armstrong Pharmaceuticals says FDA "assured" the firm that it can sell a proposed reformulated epinephrine inhaler OTC, if approved, despite opponents who say asthma relief is an inappropriate self-medication indication

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS103260

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel